White blood cells scattergram as a valuable tool for COVID-19 screening: A multicentric study.

COVID-19 SARS-Cov-2 WBC scattergram coronavirus plasmacytoid lymphocytes

Journal

International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213

Informations de publication

Date de publication:
04 Mar 2024
Historique:
received: 18 09 2023
accepted: 14 02 2024
medline: 5 3 2024
pubmed: 5 3 2024
entrez: 5 3 2024
Statut: aheadofprint

Résumé

New tools have been developed to distinguish the COVID-19 diagnosis from other viral infections presenting similar symptomatology and mitigate the lack of sensitivity of molecular testing. We previously identified a specific "sandglass" aspect on the white blood cells (WBC) scattergram of COVID-19 patients, as a highly reliable COVID-19 screening test (sensitivity: 85.9%, specificity: 83.5% and positive predictive value: 94.3%). We then decided to validate our previous data in a multicentric study. This retrospective study involved 817 patients with flu-like illness, among 20 centers, using the same CBC instrument (XN analyzer, SYSMEX, Japan). After training, one specialist per center independently evaluated, under the same conditions, the presence of the "sandglass" aspect of the WDF scattergram, likely representing plasmacytoid lymphocytes. Overall, this approach showed sensitivity: 59.0%, specificity: 72.9% and positive predictive value: 77.7%. Sensitivity improved with subgroup analysis, including in patients with lymphopenia (65.2%), patients presenting symptoms for more than 5 days (72.3%) and in patients with ARDS (70.1%). COVID-19 patients with larger plasmacytoid lymphocyte cluster (>15 cells) more often have severe outcomes (70% vs. 15% in the control group). Our findings confirm that the WBC scattergram analysis could be added to a diagnostic algorithm for screening and quickly categorizing symptomatic patients as either COVID-19 probable or improbable, especially during COVID-19 resurgence and overlapping with future influenza epidemics. The observed large size of the plasmacytoid lymphocytes cluster appears to be a hallmark of COVID-19 patients and was indicative of a severe outcome. Furthers studies are ongoing to evaluate the value of the new hematological parameters in combination with WDF analysis.

Identifiants

pubmed: 38439664
doi: 10.1111/ijlh.14257
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 John Wiley & Sons Ltd.

Références

Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med CCLM. 2020;58(7):1063-1069. doi:10.1515/cclm-2020-0240
Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med CCLM. 2020;58(7):1021-1028. doi:10.1515/cclm-2020-0369
Wynants L, Calster BV, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ. 2020;369:m1328. doi:10.1136/bmj.m1328
Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371:m3731. doi:10.1136/bmj.m3731
Osman J, Lambert J, Templé M, et al. Rapid screening of COVID-19 patients using white blood cell scattergrams, a study on 381 patients. Br J Haematol. 2020;190(5):718-722. doi:10.1111/bjh.16943
van Mirre E, Vrielink GJ, Tjon-a-Tsoi N, Hendriks H, de Kieviet W, ten Boekel E. Sensitivity and specificity of the high fluorescent lymphocyte count-gate on the Sysmex XE-5000 hematology analyzer for detection of peripheral plasma cells. Clin Chem Lab Med. 2011;49(4):685-688. doi:10.1515/CCLM.2011.100
Linssen J, Jennissen V, Hildmann J, et al. Identification and quantification of high fluorescence-stained lymphocytes as antibody synthesizing/secreting cells using the automated routine hematology analyzer XE-2100. Cytom B Clin Cytom. 2007;72(3):157-166. doi:10.1002/cyto.b.20150
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet Lond Engl. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7
Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev Med Virol. 2021;31(3):e2179. doi:10.1002/rmv.2179
Piroth L, Cottenet J, Mariet AS, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9(3):251-259. doi:10.1016/S2213-2600(20)30527-0
Yip CYC, Yap ES, Mel SD, et al. Temporal changes in immune blood cell parameters in COVID-19 infection and recovery from severe infection. Br J Haematol. 2020;190(1):33-36. doi:10.1111/bjh.16847
Martens RJH, van Adrichem AJ, Mattheij NJA, et al. Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzer. Clin Chem Lab Med. 2021;59(4):783-793. doi:10.1515/cclm-2020-1529
Wang Z, He Y, Shu H, et al. High fluorescent lymphocytes are increased in COVID-19 patients. Br J Haematol. 2020;190(2):e76-e78. doi:10.1111/bjh.16867
Rolla R, Vidali M, Puricelli C, et al. Reduced activity of B lymphocytes, recognised by Sysmex XN-2000™ haematology analyser, predicts mortality in patients with coronavirus disease 2019. Int J Lab Hematol. 2021;43(1):e5-e8. doi:10.1111/ijlh.13331
Linssen J, Ermens A, Berrevoets M, et al. A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study. eLife. 2020;9:e63195. doi:10.7554/eLife.63195

Auteurs

Jennifer Osman (J)

Department of Hematobiology, CH Versailles, Le Chesnay, France.

Cécile Gonnin (C)

Department of Hematobiology, CH Versailles, Le Chesnay, France.

Jérome Lambert (J)

Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
INSERM UMR1153 ECSTRRA Team, Paris, France.

Céline Behier (C)

Laboratory of Biology, Centre Hospitalier d'Angoulême, Angoulême, France.

Nicolas Chapuis (N)

Department of Hematobiology, Cochin Hospital, Paris, HP, France.

Simon Chevalier (S)

Department of Hematobiology, Biology and pathology Institute, CHU Grenoble Alpes, Grenoble, France.

Jérôme Debus (J)

Department of Hematobiology and Transfusion, Hôpital Louis-Mourier, Colombes, France.

Anne Delaval (A)

Department of Hematobiology, CH Robert Ballanger, Aulnay-sous-Bois, France.

Maxime Depoorter (M)

Department of Hematobiology, Centre Hospitalier Régional de la Haute Senne, Soignies, Belgium.

Cécile Dumas (C)

Department of Hematobiology, Hospices Civils de Lyon, Lyon, France.

Amély Dumesges (A)

Laboratory of Hematology, Saint-Antoine Hospital, Paris, France.

Pascale Dussert (P)

Laboratory of Nord Franche-Comté Hospital, Trévenans, France.

Corinne Ferrero Vacher (CF)

Department of Hematobiology, Pasteur Hospital, Nice, France.

Frédérique Dubois-Galopin (F)

Laboratory of Hematology, University Hospital of Toulouse, Toulouse, France.

Delphine Gerard (D)

Laboratory of Hematology, Nancy University Hospital, Nancy, France.

Pauline Gravière Bollotte (PG)

Laboratory of Hematology, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Bron, France.

Geoffroy Guignedoux (G)

Laboratory of Hematology, Centre Hospitalier Rene Dubos, Pontoise, France.

Caroline Mayeur-Rousse (C)

Laboratory of Hematology, CHU de Strasbourg, Strasbourg, France.

Delphine Mercier-Bataille (D)

Cerballiance Provence Laboratory, Marseille, France.

Emily Ronez (E)

Laboratory of Hematology, Ambroise Paré University Hospital, Boulogne-Billancourt, France.

Catherine Trichet (C)

Service d'Hématologie Biologique, Hôpital Beaujon, Clichy, France.

Margaux Wiber (M)

Laboratory of Hematology, Angers University Hospital, Angers, France.

Victoria Raggueneau (V)

Department of Hematobiology, CH Versailles, Le Chesnay, France.

Classifications MeSH